title: Timosaponin B-II inhibits lipopolysaccharide-induced acute lung toxicity via TLR/NF-κB pathway.
abstract: Timosaponin B-II (TB), a main bioactive compound in Anemarrhena asphodeloides Bunge, has various kinds of pharmacological activities, the present study aimed to investigate the protective role of TB on lipopolysaccharide (LPS)-induced acute lung injury (ALI). ALI was induced in mice by intratracheal instillation of LPS, and TB (20 and 60 mg/kg) was given orally 1 h prior to LPS administration. After 6 h, bronchoalveolar lavagefluid (BALF) and lung tissue were collected. TB decreased LPS-induced evident lung histopathological changes, lung wet-to-dry weight (W/D) ratio and lung myeloperoxidase (MPO) activity. In addition, TB inhibited inflammatory cells and cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in BALF. Furthermore, we demonstrated that TB inhibited the Toll-like receptor-2 (TLR2), Toll-like receptor-4 (TLR4), myeloid differentiation primary response gene-88 (MyD88), nuclear factor-κB (NF-κB) p65 in LPS-induced ALI. These results showed that administration of TB prior to LPS improves ALI, possibly mediating ALI through suppressing TLR/NF-κB pathway activation.
authors.affiliation: a Department of Pharmacy , Changchun University of Chinese Medicine , Changchun , China.
authors.forename: Tianzhu
authors.initials: T
authors.lastname: Zhang
authors.affiliation: a Department of Pharmacy , Changchun University of Chinese Medicine , Changchun , China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: a Department of Pharmacy , Changchun University of Chinese Medicine , Changchun , China.
authors.forename: Shumin
authors.initials: S
authors.lastname: Wang
authors.affiliation: a Department of Pharmacy , Changchun University of Chinese Medicine , Changchun , China.
authors.forename: Chunhua
authors.initials: C
authors.lastname: Ma
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D015153:Blotting, Western; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity*; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008807:Mice, Inbred BALB C; D012503:Saponins / Q000008:administration & dosage / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use*; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors*; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors*; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors*
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D012503:Saponins; D013256:Steroids; C493486:Tlr2 protein, mouse; C493487:Tlr4 protein, mouse; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051996:Transcription Factor RelA; C482199:lipopolysaccharide, E coli O55-B5; C523027:timosaponin B-II
keywords: Lipopolysaccharide; TLR/NF-κB pathway; lung injury; timosaponin B-II